ID 402066447 · FY 2018–2024 · 7 years
კომპანიის ძირითადი საქმიანობა არის საცალო ვაჭრობა ფარმაცევტული საქონლით.
Bars are revenue on the left axis; lines are EBITDA and net margin on the right.
| Ratio | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Margins | |||||||
| Gross Margin | 56.6% | 56.2% | 60.9% | 44.0% | 37.5% | 59.8% | 62.7% |
| EBITDA Margin | 35.2% | 33.9% | 22.0% | 2.7% | 14.3% | 7.9% | -6.4% |
| EBITDAR | 1,535 | 2,240 | 1,635 | 335 | 812 | 433 | -283 |
| EBITDAR Margin | 38.3% | 35.5% | 23.3% | 4.5% | 15.9% | 8.7% | -6.1% |
| EBIT Margin | 35.0% | 33.5% | 21.5% | 0.9% | 13.5% | 6.5% | -7.4% |
| Net Profit Margin | 35.0% | 33.6% | 22.9% | -4.5% | 17.1% | 14.2% | 0.6% |
| Operating Expense % of Sales | 21.4% | 22.3% | 38.9% | 41.4% | 23.2% | 51.9% | 69.2% |
| Returns | |||||||
| Return on Assets (ROA) | 70.6% | 111.8% | 51.1% | -16.6% | 33.2% | 22.1% | 1.1% |
| Return on Equity (ROE) | 104.6% | 116.2% | 58.1% | -58.2% | 66.0% | 37.8% | 1.8% |
| ROIC [EBIT / Invested Capital] | 75.5% | 120.1% | 49.5% | 6.0% | 55.1% | 12.5% | -16.8% |
| Leverage & liquidity | |||||||
| Debt-to-Assets | 27.4% | 0.0% | 11.2% | 29.7% | 12.8% | 25.7% | 20.1% |
| Debt-to-Equity | 0.41x | 0.00x | 0.13x | 1.04x | 0.25x | 0.44x | 0.32x |
| Debt-to-EBITDA | 0.39x | 0.00x | 0.23x | 2.97x | 0.46x | 2.09x | N/A |
| Equity-to-Assets | 67.4% | 96.3% | 87.9% | 28.4% | 50.3% | 58.4% | 62.5% |
| Net Debt | 516 | -61 | 294 | 580 | -77 | 741 | 501 |
| Cash & Equivalents | 28 | 61 | 58 | 12 | 414 | 76 | 2 |
| Total Debt | 545 | N/A | 352 | 592 | 337 | 817 | 503 |
| Efficiency & working capital | |||||||
| Inventory Turnover | N/A | 2.38x | 1.88x | N/A | N/A | N/A | N/A |
| Days Inventory Outstanding (DIO) | N/A | 153.1 | 193.6 | N/A | N/A | N/A | N/A |
| Receivables Turnover | 4.83x | 13.62x | 4.92x | 9.36x | 11.32x | 12.87x | 7.69x |
| Days Sales Outstanding (DSO) | 75.5 | 26.8 | 74.1 | 39.0 | 32.2 | 28.4 | 47.5 |
| Payables Turnover | 19.69x | 39.82x | 99.80x | 7.34x | 3.83x | 4.34x | 28.59x |
| Days Payable Outstanding (DPO) | 18.5 | 9.2 | 3.7 | 49.8 | 95.3 | 84.0 | 12.8 |
| Cash Conversion Cycle | 57.0 days | 170.7 days | 264.1 days | -10.8 days | -63.0 days | -55.7 days | 34.7 days |
| Asset Turnover | 2.02x | 3.33x | 2.23x | 3.71x | 1.94x | 1.56x | 1.86x |
| Cash flow & dividends | |||||||
| Operating Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow (OCF − Capex proxy) | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash Conversion (OCF / EBITDA) | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends Declared | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividend Payout Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Money rows — EBITDAR, net debt, cash, total debt, operating and free cash flow, dividends declared — are in ₾ '000. Margins, returns and payout are percentages; turnover and leverage are multiples; DIO/DSO/DPO are days. Hover a metric name for its definition.
Shareholders, directors and group links from the companyinfo.ge public register — as filed, so stakes need not sum to 100% where a holding is undisclosed.
Companies sharing this sub-sector, ranked by how close their latest revenue is to this one — not a curated comp set.
Ownership & directors from companyinfo.ge (public corporate registry).